Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 13cyclopia sequence 7Neoplasms 6Multiple Myeloma 6Fatigue 6Neoplasms, Plasma Cell 5Neoplasm Metastasis 4Lung Neoplasms 4Dyspnea 4Carcinoma, Non-Small-Cell Lung 4Anxiety Disorders 4Uterine Cervical Neoplasms 3Tobacco Use Cessation 3Prostatic Neoplasms 3Primary Myelofibrosis 3Leukemia 3Head and Neck Neoplasms 3Depression 3Carcinoma, Renal Cell 3Vomiting 2Smoking Cessation 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Polycythemia Vera 2Parasomnias 2Pancreatic Neoplasms 2Pain 2Osteosarcoma 2Kidney Neoplasms 2Hodgkin Disease 2Hematologic Neoplasms 2

Interventions

Dexamethasone 43Cyclophosphamide 38fludarabine phosphate 27Cytarabine 26Rituximab 24Methotrexate 21Lenalidomide 21Bortezomib 21Calcium Dobesilate 20fludarabine 19Peripheral Blood Stem Cell Transplantation 19Whole-Body Irradiation 16Mycophenolic Acid 16pembrolizumab 15Gemcitabine 15Etoposide 15pomalidomide 14Melphalan 14Vincristine 13Filgrastim 13Busulfan 13Tacrolimus 12Cyclosporine 12Carboplatin 12Paclitaxel 11carfilzomib 10durvalumab 9Doxorubicin 9Cetuximab 9Brentuximab Vedotin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Recurrence × Surveys and Questionnaires × Clear all
NCT02514252 2021-05-18

Sublingual Fentanyl for the Management of Breakthrough Pain

M.D. Anderson Cancer Center

Phase 2 Terminated
6 enrolled 8 charts

Agnosia, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡